{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:11:28Z","timestamp":1768695088031,"version":"3.49.0"},"reference-count":34,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1393,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1600-0404.2011.01600.x","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T07:01:25Z","timestamp":1320735685000},"page":"48-56","source":"Crossref","is-referenced-by-count":18,"special_numbering":"supplement s192","title":["Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin"],"prefix":"10.1155","volume":"124","author":[{"given":"R. C.","family":"Sergott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. A.","family":"Westall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,8]]},"reference":[{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB1|cit1","volume-title":"SABRIL\u00ae [prescribing information]","year":"2010"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01600.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0404.2011.01597.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major European trials","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01600.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0404.2011.01599.x","article-title":"Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing","volume":"124","author":"Carmant","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01600.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0404.2011.01598.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major US trials","volume":"124","author":"Faught","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ICU.0b013e32833f0085","article-title":"Recommendations for visual evaluations of patients treated with vigabatrin","volume":"21","author":"Sergott","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/01658100903582498","article-title":"Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin","volume":"34","author":"Sergott","year":"2010","journal-title":"Neuro-opthalmology"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB7|cit7","first-page":"91","volume-title":"Neuro-ophthalmology, section 5, basic and clinical science course","author":"American Academy of Ophthalmology","year":"2009"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB8|cit8","first-page":"7","article-title":"Introduction to formal visual field testing: Goldmann and Humphrey perimetry","volume":"18","author":"Cohen","year":"1999","journal-title":"J Ophthalmic Nurs Technol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00023210-200115030-00005","article-title":"Visual field defects with vigabatrin: epidemiology and therapeutic implications","volume":"15","author":"K\u00e4lvi\u00e4inen","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archopht.118.9.1187","article-title":"Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study","volume":"118","author":"Keltner","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/IJG.0b013e31815f531d","article-title":"Learning effect of Humphrey matrix frequency doubling technology perimetry in patients with ocular hypertension","volume":"17","author":"Centofanti","year":"2008","journal-title":"J Glaucoma"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB12|cit12","first-page":"33","volume-title":"Retina and vitreous, section 12, basic and clinical science course","author":"American Academy of Ophthalmology","year":"2010"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB13|cit13","volume-title":"Pediatric ophthalmology and strabismus","author":"Westall","year":"2012"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10633-008-9155-4","article-title":"ISCEV Standard for full-field clinical electroretinography (2008 update)","volume":"118","author":"Marmor","year":"2009","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1023\/B:DOOP.0000005332.88367.b8","article-title":"Development of ERG responses: the ISCEV rod, maximal and cone responses in normal subjects","volume":"107","author":"Fulton","year":"2003","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1023\/A:1001856911730","article-title":"Time courses for maturation of electroretinogram responses from infancy to adulthood","volume":"96","author":"Westall","year":"1999","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB17|cit17","first-page":"19","volume-title":"Retina and vitreous, section 12, basic and clinical science course","author":"American Academy of Ophthalmology","year":"2010"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB18|cit18","unstructured":"Sergott RC Faught E Torri S Wesche D Retinal structure and function in adult patients with refractory complex partial seizures treated with SABRIL \u00ae (vigabatrin): an open-label, Phase IV study"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1034\/j.1600-0420.2003.00125.x","article-title":"Characterization of vigabatrin-associated optic atrophy","volume":"81","author":"Fris\u00e9n","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.ophtha.2004.03.036","article-title":"Characteristic retinal atrophy with secondary \u201cinverse\u201d optic atrophy identifies vigabatrin toxicity in children","volume":"111","author":"Buncic","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB21|cit21","doi-asserted-by":"crossref","unstructured":"Plant GT Sergott RC Understanding and interpreting vision safety issues with vigabatrin 2011 124 Suppl. 192 57 71","DOI":"10.1111\/j.1600-0404.2011.01601.x"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","article-title":"Vigabatrin visual toxicity: evolution and dose dependence","volume":"42","author":"Malmgren","year":"2001","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1600-0420.2003.00184.x","article-title":"Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship","volume":"82","author":"Fris\u00e9n","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/0883073810390213","article-title":"Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?","volume":"26","author":"McCoy","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/B:DOOP.0000005338.51554.e3","article-title":"Longitudinal changes in photopic OPs occurring with vigabatrin treatment","volume":"107","author":"Morong","year":"2003","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1014656626174","article-title":"The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin","volume":"104","author":"Westall","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/B:DOOP.0000005339.23258.8f","article-title":"Changes in the electroretinogram resulting from discontinuation of vigabatrin in children","volume":"107","author":"Westall","year":"2003","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/A:1014643528474","article-title":"Vigabatrin: its effect on the electrophysiology of vision","volume":"104","author":"Harding","year":"2002","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1528-1157.2000.tb00117.x","article-title":"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction","volume":"41","author":"Harding","year":"2000","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.55.3.347","article-title":"Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss","volume":"55","author":"Harding","year":"2000","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/B:DOOP.0000005337.39947.83","article-title":"Examining visual field defects in the paediatric population exposed to vigabatrin","volume":"107","author":"Spencer","year":"2003","journal-title":"Doc Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1167\/iovs.04-0559","article-title":"Reduced visual function associated with infantile spasms in children on vigabatrin therapy","volume":"46","author":"Hammoudi","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1111\/j.1600-0404.2011.01600.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1167\/iovs.06-0755","article-title":"Contrast sensitivity is reduced in children with infantile spasms","volume":"48","author":"Mirabella","year":"2007","journal-title":"Invest Ophthalomol Vis Sci"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01600.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0404.2011.01603.x","article-title":"Balancing the clinical benefit of vigabatrin with its associated risk of vision loss","volume":"124","author":"Pellock","year":"2011","journal-title":"Acta Neurol Scand"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2011.01600.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2011.01600.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:49:41Z","timestamp":1671540581000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2011.01600.x"}},"subtitle":["Vision testing of vigabatrin-treated patients"],"short-title":[],"issued":{"date-parts":[[2011,11,8]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2011.01600.x","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,8]]}}}